Clinical Trial Search

Primary: Percentage of Trials Correct On Working Memory Test — 87.69; 91.57; 88.01; 91.68 percentage of correct trials — p=>0.05

Primary: Percentage of Participants Completing the Study — 90 Percentage of participants

Primary: Change From Baseline in California Verbal Learning Task Score — 3.04; 5.17; 4.22; 7.04 score on a scale

Primary: Change in Cognitive Function as Measured Using the Extended Mini Mental State Exam — 0.58 Change on a scale

Primary: Complutense Verbal Learning Test (TAVEC) - Memory — 0.94; -0.81; 1.65; -0.31 units on a scale

Primary: Change in the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) — -0.89; 0.55 score

Primary: Knowledge of Memory Aging Questionnaire-Revised — 19.8; 19.5 units on a scale

Primary: Attention Network Effects

Primary: Change in Hippocampal-dependent Learning — -.00369; .00404 learning rate (proportion correct/trial) — p=<.05

Primary: FCI Score at Follow-up — 147.3; 164.0; 123.3; 150.8 points awarded for correct items

Primary: CRM Performance During First Sim Scenario Assessed by Ottawa Global Rating Scale (GRS) — -0.299 Pearson correlation coefficient — p=0.039

Primary: Initial Eye-movements Toward Target and Distractor Shapes Measured by an Eye-tracker — 3.8; 4.4; 3.6; 4.5 percentage of first saccades

Primary: Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue — .011; .007; .009; .006 Difference in metabolite amplitude

Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale

Primary: Number of Participants With a Decline of 6 Points on the Hopkins Verbal Learning Test-Revised (HVLT-R) — 1; 9 Participants — p=.02

Primary: Overall Score Changes From Baseline by Magnesium Treatment vs. Placebo — 1.1; 0.6 score on a scale — p=0.20

Primary: Change in Depression Severity (Measured by Montgomery Asberg Depression Rating Scale) — 25.26; 1.03; 13.78; 1.08 score on a scale — p=< 0.025

Primary: Change in Mean Global Composite Cognition Score From Baseline — 0.2; 0.2 Z-score — p=0.259

Primary: Blood Brain Barrier Penetration of RAPA — 0 ng/ml

Primary: Change Executive Language Functions (Category Verbal Fluency) — 5; -1 Number of Fluent Words within 60 seconds

Primary: Change in Objective Cognitive Performance Composite z Score — .24; .14 Z score

Primary: Change in Total Fluid Cognitive Score — 6.14; 3.71; 106.06; 105.85 score on a scale

Primary: Memory Composite Score — -0.11; -0.14; -0.13; -0.12 Z-score — p=0.50

Primary: Rivermead Behavioral Memory Test — 11.08; 11.2; 12.31 units on a scale

Primary: Total Number of Goals Improved to Criterion on the Canadian Occupational Performance Measure (COPM) — 50; 19.6; 50; 32.6 percentage of untrained goals improved — p=0.03

Primary: Change in Cognitive Function — 0.28; .65; 1.84; -.73 T score

Primary: Agreement Analysis (Agreement to Reference Standard) - Test Group — 76; 18; 2; 8 Participants

Primary: Number of Participants With a Diagnosis of a Cognitive Impairment Disorder Measured by Pharmacological Interventions for the Management of Cognitive Impairment. — 0; 0…

Primary: Percentage of Recruited Subjects Able to Comply With the Protocol — 12; 13; 3; 14 Participants

Primary: New Occurrence in Dementia Care-A Composite Endpoint Including New Cognitive Diagnoses, Laboratory Investigations Related to Cognitive Impairment, New Dementia…